Epidemiology and treatment of congenital fibrinogen deficiency

Research output: Contribution to journalArticle

44 Citations (Scopus)

Abstract

Congenital fibrinogen deficiency is a rare bleeding disorder, affecting either the quantity (afibrinogenemia, hypofibrinogenemia) or quality (dysfibrinogenemia) of circulating fibrinogen. There is a strong association between fibrinogen activity levels and clinical bleeding severity. Patients with afibrinogenemia experience frequent, often severe, spontaneous bleeds into the muscles and joints and are at significant risk of intracranial hemorrhage. Patients with hypofibrinogenemia are usually asymptomatic; however, they are vulnerable to bleeding after trauma. Dysfibrinogenemia is associated with both spontaneous bleeding and a relatively high risk of thrombosis. Fibrinogen replacement therapy is effective in treating bleeding episodes in congenital fibrinogen deficiency. Fibrinogen concentrates are the preferred treatment option and guidelines now exist for their on-demand use and to manage surgery. Prophylaxis may benefit patients with afibrinogenemia and others with a severe bleeding tendency. The dose and frequency of administration should be adjusted to maintain a fibrinogen activity level >0.5-1.0 g/L. Pregnant women with afibrinogenemia require prophylactic factor replacement as early as possible during pregnancy, continuing throughout pregnancy, and after the birth. Fibrinogen replacement should also be considered in pregnant women with other fibrinogen deficiencies. The risk of thrombosis presents an additional management challenge in these patients, often necessitating the concurrent use of anticoagulants and fibrinogen. Although basic guidelines have been developed, further studies are needed to help optimize treatment in different patient groups under different clinical circumstances and to improve our understanding of thrombotic events.

Original languageEnglish
JournalThrombosis Research
Volume130
Issue numberSUPPL. 2
DOIs
Publication statusPublished - Dec 2012

Fingerprint

Afibrinogenemia
Fibrinogen
Epidemiology
Hemorrhage
Therapeutics
Pregnant Women
Thrombosis
Guidelines
Pregnancy
Intracranial Hemorrhages
Anticoagulants
Joints
Parturition
Muscles
Wounds and Injuries

Keywords

  • Afibrinogenemia
  • Congenital fibrinogen deficiency
  • Dysfibrinogenemia
  • Epidemiology
  • Fibrinogen concentrate
  • Fibrinogen replacement
  • Haemocomplettan® P
  • Hypofibrinogenemia
  • Pregnancy
  • RiaSTAP®
  • Surgery

ASJC Scopus subject areas

  • Hematology

Cite this

Epidemiology and treatment of congenital fibrinogen deficiency. / Peyvandi, Flora.

In: Thrombosis Research, Vol. 130, No. SUPPL. 2, 12.2012.

Research output: Contribution to journalArticle

@article{155e42d57b734d239e5e9559128b4c5b,
title = "Epidemiology and treatment of congenital fibrinogen deficiency",
abstract = "Congenital fibrinogen deficiency is a rare bleeding disorder, affecting either the quantity (afibrinogenemia, hypofibrinogenemia) or quality (dysfibrinogenemia) of circulating fibrinogen. There is a strong association between fibrinogen activity levels and clinical bleeding severity. Patients with afibrinogenemia experience frequent, often severe, spontaneous bleeds into the muscles and joints and are at significant risk of intracranial hemorrhage. Patients with hypofibrinogenemia are usually asymptomatic; however, they are vulnerable to bleeding after trauma. Dysfibrinogenemia is associated with both spontaneous bleeding and a relatively high risk of thrombosis. Fibrinogen replacement therapy is effective in treating bleeding episodes in congenital fibrinogen deficiency. Fibrinogen concentrates are the preferred treatment option and guidelines now exist for their on-demand use and to manage surgery. Prophylaxis may benefit patients with afibrinogenemia and others with a severe bleeding tendency. The dose and frequency of administration should be adjusted to maintain a fibrinogen activity level >0.5-1.0 g/L. Pregnant women with afibrinogenemia require prophylactic factor replacement as early as possible during pregnancy, continuing throughout pregnancy, and after the birth. Fibrinogen replacement should also be considered in pregnant women with other fibrinogen deficiencies. The risk of thrombosis presents an additional management challenge in these patients, often necessitating the concurrent use of anticoagulants and fibrinogen. Although basic guidelines have been developed, further studies are needed to help optimize treatment in different patient groups under different clinical circumstances and to improve our understanding of thrombotic events.",
keywords = "Afibrinogenemia, Congenital fibrinogen deficiency, Dysfibrinogenemia, Epidemiology, Fibrinogen concentrate, Fibrinogen replacement, Haemocomplettan{\circledR} P, Hypofibrinogenemia, Pregnancy, RiaSTAP{\circledR}, Surgery",
author = "Flora Peyvandi",
year = "2012",
month = "12",
doi = "10.1016/S0049-3848(13)70004-5",
language = "English",
volume = "130",
journal = "Thrombosis Research",
issn = "0049-3848",
publisher = "Elsevier Limited",
number = "SUPPL. 2",

}

TY - JOUR

T1 - Epidemiology and treatment of congenital fibrinogen deficiency

AU - Peyvandi, Flora

PY - 2012/12

Y1 - 2012/12

N2 - Congenital fibrinogen deficiency is a rare bleeding disorder, affecting either the quantity (afibrinogenemia, hypofibrinogenemia) or quality (dysfibrinogenemia) of circulating fibrinogen. There is a strong association between fibrinogen activity levels and clinical bleeding severity. Patients with afibrinogenemia experience frequent, often severe, spontaneous bleeds into the muscles and joints and are at significant risk of intracranial hemorrhage. Patients with hypofibrinogenemia are usually asymptomatic; however, they are vulnerable to bleeding after trauma. Dysfibrinogenemia is associated with both spontaneous bleeding and a relatively high risk of thrombosis. Fibrinogen replacement therapy is effective in treating bleeding episodes in congenital fibrinogen deficiency. Fibrinogen concentrates are the preferred treatment option and guidelines now exist for their on-demand use and to manage surgery. Prophylaxis may benefit patients with afibrinogenemia and others with a severe bleeding tendency. The dose and frequency of administration should be adjusted to maintain a fibrinogen activity level >0.5-1.0 g/L. Pregnant women with afibrinogenemia require prophylactic factor replacement as early as possible during pregnancy, continuing throughout pregnancy, and after the birth. Fibrinogen replacement should also be considered in pregnant women with other fibrinogen deficiencies. The risk of thrombosis presents an additional management challenge in these patients, often necessitating the concurrent use of anticoagulants and fibrinogen. Although basic guidelines have been developed, further studies are needed to help optimize treatment in different patient groups under different clinical circumstances and to improve our understanding of thrombotic events.

AB - Congenital fibrinogen deficiency is a rare bleeding disorder, affecting either the quantity (afibrinogenemia, hypofibrinogenemia) or quality (dysfibrinogenemia) of circulating fibrinogen. There is a strong association between fibrinogen activity levels and clinical bleeding severity. Patients with afibrinogenemia experience frequent, often severe, spontaneous bleeds into the muscles and joints and are at significant risk of intracranial hemorrhage. Patients with hypofibrinogenemia are usually asymptomatic; however, they are vulnerable to bleeding after trauma. Dysfibrinogenemia is associated with both spontaneous bleeding and a relatively high risk of thrombosis. Fibrinogen replacement therapy is effective in treating bleeding episodes in congenital fibrinogen deficiency. Fibrinogen concentrates are the preferred treatment option and guidelines now exist for their on-demand use and to manage surgery. Prophylaxis may benefit patients with afibrinogenemia and others with a severe bleeding tendency. The dose and frequency of administration should be adjusted to maintain a fibrinogen activity level >0.5-1.0 g/L. Pregnant women with afibrinogenemia require prophylactic factor replacement as early as possible during pregnancy, continuing throughout pregnancy, and after the birth. Fibrinogen replacement should also be considered in pregnant women with other fibrinogen deficiencies. The risk of thrombosis presents an additional management challenge in these patients, often necessitating the concurrent use of anticoagulants and fibrinogen. Although basic guidelines have been developed, further studies are needed to help optimize treatment in different patient groups under different clinical circumstances and to improve our understanding of thrombotic events.

KW - Afibrinogenemia

KW - Congenital fibrinogen deficiency

KW - Dysfibrinogenemia

KW - Epidemiology

KW - Fibrinogen concentrate

KW - Fibrinogen replacement

KW - Haemocomplettan® P

KW - Hypofibrinogenemia

KW - Pregnancy

KW - RiaSTAP®

KW - Surgery

UR - http://www.scopus.com/inward/record.url?scp=84874642060&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84874642060&partnerID=8YFLogxK

U2 - 10.1016/S0049-3848(13)70004-5

DO - 10.1016/S0049-3848(13)70004-5

M3 - Article

C2 - 23439004

AN - SCOPUS:84874642060

VL - 130

JO - Thrombosis Research

JF - Thrombosis Research

SN - 0049-3848

IS - SUPPL. 2

ER -